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Abstract: Chronic thromboembolic pulmonary hypertension (CTEPH) is a disease of the 
pulmonary vascular bed that is characterized by elevations in the mean pulmonary artery pressure 
in the setting of perfusion defects on ventilation–perfusion scan, and subsequently confirmed 
by pulmonary angiography. CTEPH, or World Health Organization (WHO) group 4 pulmonary 
hypertension, is a result of unresolved thromboembolic obstruction in the pulmonary arteries. 
Pulmonary endarterectomy (PEA) is the treatment of choice for CTEPH as it is a potentially 
curative therapy. However, up to one-third of patients are not candidates for the surgery, either 
due to distal and inaccessible nature of the lesions or comorbid conditions. Due to remodeling 
that occurs in nonobstructed pulmonary vessels, a portion of patients who have undergone 
PEA have residual CTEPH after the procedure, attributable to high shear stress prior to PEA. 
This phenomenon has led to the understanding of a so-called “two-compartment model” of 
CTEPH, opening the door to pharmacologic treatment strategies. In 2013, riociguat, a soluble 
guanylate cyclase stimulator, was approved in the US and Europe for the treatment of inoper-
able or persistent/recurrent CTEPH. This article reviews the current management of CTEPH 
with a focus on riociguat.
Keywords: riociguat, chronic thromboembolic pulmonary hypertension, pulmonary endart-
erectomy, pulmonary hypertension
Introduction
Pulmonary hypertension (PH) defines a group of clinical conditions presenting 
with abnormal elevation in the pulmonary circulation pressure ultimately leading to 
right ventricular failure if left untreated.1 A resting mean pulmonary artery pressure 
(mPAP) $25 mmHg on right heart catheterization (RHC) is diagnostic for PH.2 PH is 
further categorized into five groups based on the underlying etiology of the abnormally 
elevated mPAP: pulmonary arterial hypertension (PAH), PH due to left heart disease, 
PH due to lung disease or hypoxic conditions, chronic thromboembolic pulmonary 
hypertension (CTEPH), and PH of unclear multifactorial etiology.3 These are desig-
nated as Groups I–V, respectively.
CTEPH is caused by persistent obstruction of pulmonary arteries following pul-
monary embolism (PE). The estimated prevalence of CTEPH after an acute PE is 
0.1%–4.0% after 2 years.4 However, up to 25% of patients have no previous diagnosis 
of PE.5 If suspected, CTEPH is screened for with a transthoracic echocardiogram and 
radionuclide ventilation/perfusion (VQ) scan, followed by an RHC with pulmonary 
angiography for disease confirmation and assessment of operability.6 The current 
treatment of choice for CTEPH includes lifelong anticoagulation and referral to 
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specialized high-volume centers for pulmonary endarterec-
tomy (PEA) in the event that the clot is not prohibitively 
distal.4,7 It has been observed that the degree of pulmonary 
vascular resistance (PVR) does not directly correlate with 
the clot burden which contributed to an eventual under-
standing of a two-compartment model of disease, with 
vascular remodeling that occurs in vessels unobstructed by 
clot. This understanding, in addition to a cohort of patients 
with recurrent CTEPH following PEA, opened the door to 
pharmacologic therapy.8 Drug therapy utilized in CTEPH 
prior to the approval of riociguat in 2013 was off-label and 
provided an unclear benefit given the mixed results of previ-
ous clinical trials.9
Riociguat is the first approved medication from the 
soluble guanylate cyclase (sGC) stimulator class and the sole 
agent approved for CTEPH.10 Riociguat was approved based 
on the demonstration of significantly improved exercise 
capacity in those with inoperable or symptomatic disease 
despite PEA.11
CTEPH review
CTEPH is defined as an elevated mPAP $25 mmHg caused 
by persistent obstruction of the pulmonary arteries after PE 
that has not resolved despite 3 months of therapeutic anti-
coagulation.12 Nonresolving acute PE is the most common 
cause of CTEPH and can occur after recurrent episodes.4 
Up to 50% of patients have residual perfusion defects 6 
months after diagnosis of PE.12 The estimated prevalence 
of symptomatic CTEPH after a PE is as high as 4% at 
2 years.13 Classification of the severity of patient symp-
toms is done according to the World Health Organization 
(WHO) functional class (FC) scheme.14 The FC scheme 
ranges from I to IV, with FC I being asymptomatic to FC 
IV being severely symptomatic (Table 1). Risk factors for 
developing CTEPH after an acute PE include history of 
lower-limb varicose veins, intermediate-risk PE, size of the 
initial thrombus, elevated systolic pulmonary artery pres-
sure .50 mmHg in the acute phase and residual emboli at 
3-month follow-up.15,16 Other risk factors associated with the 
diagnosis of CTEPH include increased factor VIII levels, 
increased von Willebrand factor levels, abnormalities in 
fibrinogen, splenectomy, ventriculoatrial shunt, osteomy-
elitis, inflammatory bowel disease, antiphospholipid syn-
drome, hypothyroidism, and cancer.16 Clinical prediction 
scores are currently under development to identify patient-
specific prognostic factors associated with the progression 
of an acute PE to CTEPH.14 The mortality rate of untreated 
CTEPH is as high as 90% at 3 years.17
The current recommendation for optimal management 
of CTEPH upon diagnosis is referral to a center with expertise 
in PEA to assess surgical candidacy.6,18 PEA is the only cura-
tive treatment for CTEPH, with periprocedural mortality 
ranging from ,2% to 5% in experienced centers.19 A center 
is considered to have adequate expertise if it performs at least 
20 PEAs per year with a mortality rate ,10%.20 Despite this 
curative procedure, recent registries indicate that a signifi-
cant portion of patients are inoperable candidates (36.4%), 
do not undergo PEA despite being candidates (12.6%), or 
have persistent disease symptoms despite PEA.5,6 Prior to 
riociguat, inhaled iloprost, sildenafil, and bosentan were 
the only agents studied in patients with CTEPH.21–23 These 
agents were unable to show a statistically significant dif-
ference in 6-minute walk distance (6MWD) in the CTEPH 
population.6 Riociguat is the first agent to demonstrate a 
significant change in 6MWD and hemodynamic parameters 
in patients with inoperable disease or persistent or recurrent 
symptoms after PEA.11
Riociguat mechanism of action and 
pharmacology
Riociguat is a sGC stimulator that increases the maximal cata-
lytic rate and activation of sGC, thereby increasing the syn-
thesis of cyclic guanosine monophosphate (cGMP) in smooth 
muscle cells and producing antiproliferative effects, vasodi-
latory effects, and reducing platelet aggregation.24 In vitro, 
sGC stimulator activity is synergistic in the presence of nitric 
oxide (NO) but may also occur in an NO-independent fash-
ion.24 Riociguat increases sGC activity 73-fold independent 
of NO and 122-fold in the presence of NO, as evidenced 
by its 12 times more potent vasorelaxant properties in 
Table 1 Pulmonary hypertension functional classification
Class i Patients with pulmonary hypertension but without resulting limitation of physical activity. Ordinary physical activity does not cause 
undue dyspnea or fatigue, chest pain, or near syncope
Class ii Patients with pulmonary hypertension resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical 
activity causes undue dyspnea or fatigue, chest pain, or near syncope
Class iii Patients with pulmonary hypertension resulting in marked limitation of physical activity. They are comfortable at rest. Less than 
ordinary activity causes undue dyspnea or fatigue, chest pain, or near syncope
Class iv Patients with pulmonary hypertension with inability to carry out any physical activity without symptoms. These patients manifest signs 
of right heart failure. Dyspnea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity




Riociguat’s role in CTePH
nitrate-refractory vessels compared with glycerol trinitrate 
(an NO donor).25,26 Riociguat demonstrated ten times more 
potent vasorelaxant properties than its principle and active 
M1 metabolite, with neither entity resulting in sensitization 
or tachyphylaxis after sustained exposure.26
Phase II efficacy, safety, and dose ranging 
studies in CTePH
Riociguat was first studied in patients with CTEPH in a 
Phase II, dose-finding study.27 For the dose-finding phase, 
four patients with PAH and CTEPH were administered three 
doses of riociguat, each 1 hour apart, for a total dose of either 
2.5 or 5 mg. One patient in the high-dose group experienced 
asymptomatic hypotension while supine.27
Pharmacokinetic variables were assessed after admin-
istering a single dose of riociguat.27 The minimum dose 
was 1 mg, and the maximum dose was 2.5 mg. Time to 
maximum serum (C
max
) concentration of riociguat (T
max
) 
ranged from 15 to 90 minutes. Volume of distribution (V
d
) 
was 0.35±0.03 and 0.38±0.08 L/kg in the riociguat 1 mg 
and 2.5 mg groups, respectively, which was similar to the 
results obtained for healthy volunteers.27–29 The elimination 
half-life (t
1/2
) for riociguat was 10.0±1 and 11.7±4 hours after 
doses of 1 and 2.5 mg, respectively. The dose-adjusted C
max
 
was 1.5–2 times higher and the dose-adjusted area under the 
time–concentration curve (AUC) was three times higher than 
observed in healthy subjects.27–29 
Hemodynamic variables were assessed after NO inhala-
tional testing and, after a brief washout period, a single dose 
of riociguat.27 Mean decrease in hemodynamic parameters 
after receiving a single dose of riociguat 1 and 2.5 mg, 
respectively, was as follows: systolic blood pressure (SBP) 
by 24.0 and 28.6 mmHg; systemic vascular resistance (SVR) 
by 690.0 and 545.9 dyn⋅s/cm5; mPAP by 6.8 and 5.1 mmHg; 
and PVR by 296.5 and 168.1 dyn⋅s/cm5. Mean increase in 
cardiac index was 0.65 and 0.95 L/min/m2, respectively.27
Clinical trial data
In a 12-week multicenter, open-label, noncontrolled Phase II 
study, patients with CTEPH (n=42) or PAH (n=33) in WHO 
FC II or III received riociguat titrated according to SBP. 
Patients on background phosphodiesterase 5 inhibitor 
(PDE5) inhibitors or prostacyclin derivatives were excluded. 
Riociguat was titrated by 0.5 mg increments at 2-week 
intervals based on patient SBP from a starting dose of 1 mg 
to a maximum of 2.5 mg by mouth (PO) three times daily 
(TID) by week 8. The primary outcomes were safety and 
tolerability. Secondary outcomes were changes in 6MWD, 
WHO FC, and cardiopulmonary hemodynamics. Demo-
graphic information for the CTEPH population is presented 
in Table 2. Forty-one of the 42 (96%) enrolled patients 
with CTEPH completed the study. The tolerability results 
were not separated by PAH or CTEPH status. At the end 
of the study, 52 of the 72 (72%) patients were receiving the 
maximum dose and four (5%) were receiving the starting 
dose. One patient was receiving the 0.5 mg PO TID dose. 
The dose was reduced by 0.5 mg because of asymptomatic 
hypotension in two patients. Median SBP for the group was 
Table 2 Baseline demographic data
Demographics Ghofrani et al30 Ghofrani et al11 Simonneau et al31
Riociguat (n=41) Placebo (n=88) Riociguat (n=173) Riociguat (n=237)
Age, mean ± SD, years 63 (56–70)a 59±13 59±14 59±13
Female, n (%) 18 (44) 54 (61) 118 (68) 153 (65)
Operable status, n (%)
inoperable 41 (100) 68 (77) 121 (70) 172 (73)
Postoperative 0 (0) 20 (23) 52 (30) 65 (27)
wHO functional class, n (%)
i 0 (0) 0 3 (2) 1
ii 10 (24) 25 (28) 55 (32) 31
iii 31 (76) 60 (68) 107 (62) 65
iv 0 (0) 2 (2) 8 (5) 3 
6-minute walk distance, mean ± SD, m 390 (330–441)a 356±75 342±82 351±78
Right heart catheterization, mean ± SD
mPAP, mmHg 44 (38–51)a 44±10 45±13 –
PvR, dyn⋅s/cm5 686 (516–859)a 779±401 791±432 –
Cardiac index, L/min/m2 2.31 (1.94–2.68)a – – –
Cardiac output, L/min – 4±1 4±1 –
Notes: aMedian (interquartile range). – Not reported. From N Engl J Med, Ghofrani HA, D’Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic 
thromboembolic pulmonary hypertension, 369(4):319–329, Copyright © 2013 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical 
Society.11 Reproduced with permission of the european Respiratory Society ©: European Respiratory Journal Oct 2010, 36(4):792–799. DOi: 10.1183/09031936.30 Reproduced 
with permission of the european Respiratory Society ©: European Respiratory Journal May 2015, 45(5):1293–1302. DOi: 10.1183/09031936.00087114.31
Abbreviations: SD, standard deviation; wHO, world Health Organization; mPAP, mean pulmonary artery pressure; PvR, pulmonary vascular resistance.





significantly reduced from baseline at week 12 (120 mmHg 
vs 111 mmHg; P=0.0067). Table 3 provides the description 
of adverse effects (AEs) observed in clinical trials. The WHO 
FC improved in 22 of the 72 (31%) patients. In the CTEPH 
subgroup, 6MWD improved by 55 m (95% CI: 17–105) 
from baseline (P,0.0001). In 29 patients who underwent 
a repeat RHC at week 12, a significant change was seen in 
mPAP (-4.5 mmHg; 95% CI: -1–7), PVR (-200 dyn⋅s/cm5; 
95% CI: 155–288), and cardiac index (0.44 L/min/m2; 95% 
CI: 0.23–0.76). The authors concluded that riociguat had a 
favorable safety profile and may improve exercise capacity, 
symptoms, and hemodynamics in CTEPH.30
In a 16-week multicenter, double-blind, placebo-
controlled Phase III study, patients aged 18–80 years with 
inoperable CTEPH or persistent or recurrent CTEPH after 
PEA were randomized in a 2:1 ratio to receive riociguat 
or placebo. Additional inclusion criteria were 6MWD 
of 150–450 m, PVR .300 dyn⋅s/cm5, and mPAP .25 
mmHg. Patients on background PDE5 inhibitors, endothelin 
receptor antagonists, or prostacyclin derivatives were 
excluded. Riociguat or placebo was titrated by 0.5 mg 
increments at 2-week intervals based on a patient’s SBP 
or signs or symptoms of hypotension, from a starting dose 
of 1 mg to a maximum of 2.5 mg PO TID. The dose was 
increased if the SBP was .95 mmHg, maintained if the SBP 
was 90–94 mmHg, decreased (by 0.5 mg PO TID) if the SBP 
was ,90 mmHg without symptomatic hypotension, and tem-
porarily discontinued if SBP was ,90 mmHg with symptoms 
of hypotension. If discontinued due to an SBP ,90 mmHg, 
the medication was restarted in 24 hours with a 0.5 mg dose 
reduction. The primary outcome was change in 6MWD 
from baseline to 16 weeks. Secondary end points included 
changes in PVR, N-terminal pro-brain natriuretic peptide 
(NT-proBNP) level, WHO FC, time to clinical worsening, 
Borg dyspnea score, and AEs from baseline to 16 weeks. 
A total of 261 patients were randomized to either riociguat 
(n=173) or placebo (n=88). Demographic characteristics 
are included in Table 2. At week 16, 77% of the patients 
still in the study were taking the maximal riociguat dose 
of 2.5 mg PO TID, with 12%, 6%, 4%, and 1% taking 
riociguat at doses of 2.0, 1.5, 1.0, and 0.5 mg PO TID, 
respectively. The dose was decreased in 18 patients (10%) 
Table 3 Frequency of adverse effects described in clinical trials
Adverse effect Ghofrani et al30 (n=75)a Ghofrani et al11 (n=173) Simonneau et al31 (n=237)
Any Ae, n (%) 65 (87) 159 (92) 228 (96)
Serious Ae, n (%) 11 (15) 12 (7) 100 (42)
Drug-related Ae, n (%) 42 (56) – 109 (46)
Discontinuation of therapy due to Ae, n (%) 3 (4) 5 (3) 8 (3)
Death related to Ae, n (%) 0 (0) 2 (1) 0 (0)
Ae reported in trial population, n (%)
Abdominal pain 7 (9) – –
Constipation 5 (7) 10 (6) –
Cough – 9 (5) 32 (14)
Diarrhea 4 (5) 17 (10) 33 (14)
Dizziness 6 (8) 39 (23) 45 (19)
Dyspepsia 18 (24) 31 (18) –
Dyspnea – 8 (5) 27 (11)
Fatigue 7 (9) – –
Headache 12 (16) 43 (25) –
Hemoptysis – 3 (2) 7 (3)
Hypotension 11 (15) 16 (9) 14 (6)
increased iNR – 10 (6) –
Nasopharyngitis 4 (5) 26 (15) 55 (23)
Nausea – 19 (11) –
Peripheral edema 9 (12) 27 (16) 43 (18)
Right ventricular failure – 5 (3) –
Syncope 4 (5) 3 (2) 17 (7)
Tachycardia 9 (12) – –
Upper respiratory tract infection 4 (5) 10 (6) 26 (11)
vomiting 6 (8) 17 (10) –
vertigo 6 (8) – –
Notes: aData included for both pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension groups. – Not reported. From N Engl J Med, 
Ghofrani HA, D’Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension, 369(4):319–329, Copyright © 2013 
Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.11 Reproduced with permission of the european Respiratory Society ©: 
European Respiratory Journal Oct 2010, 36(4):792–799. DOi: 10.1183/09031936.30 Reproduced with permission of the european Respiratory Society ©: European Respiratory 
Journal May 2015, 45(5):1293–1302. DOi: 10.1183/09031936.00087114.31
Abbreviations: Ae, adverse effect; iNR, international normalized ratio.
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in the riociguat group, as compared to three (3%) in the 
placebo group. At week 16, the 6MWD had increased from 
baseline by a mean of 39 m in the riociguat group, compared 
to a 6 m decrease in the placebo group (least square mean 
difference [LSMD], 46 m; 95% CI: 25–67; P,0.001). 
PVR decreased by 226 dyn⋅s/cm5 in the riociguat group 
compared to an increase of 23 dyn⋅s/cm5 in the placebo 
group (LSMD, -246 dyn⋅s/cm5; 95% CI: -303 to -190; 
P,0.001). Riociguat was also associated with significant 
improvement in mPAP (LSMD, -5 mmHg; 95% CI: -7 
to -3; P,0.001) and cardiac output (LSMD, 0.9 L/min; 
95% CI: 0.6–1.1; P,0.001). There were also significant 
improvements in NT-proBNP level, Borg dyspnea index, 
and WHO FC. There were no differences noted in time 
to clinical worsening (P=0.17). There were no statistical 
differences noted in the occurrence of AE in the placebo 
and riociguat groups (Table 3). The authors concluded that 
riociguat significantly improved 6MWD and other clinical 
outcomes in the study population.11
A multicenter, open-label, single-group Phase IV study 
was conducted to assess the long-term safety and tolerability 
of riociguat. Of the 243 patients completing the initial 
Phase III study, 237 (98%) entered the extension study.11 
Patients previously receiving riociguat continued the same 
riociguat dose they were maintained on at the end of the 
initial study. Those in the placebo group received riociguat 
with the same dosing schematic used in the initial study.11 
The primary outcome was to assess the safety and toler-
ability of long-term riociguat treatment. Safety parameters 
included AE and laboratory variables. Exploratory efficacy 
end points included 6MWD, NT-proBNP, WHO FC, time to 
clinical worsening, and Borg dyspnea score. AEs occurred 
in 228 (96%) patients (Table 3). Thirteen deaths occurred 
during the extension study, but none were attributed to 
riociguat. Improvements in 6MWD in the riociguat group 
from the initial study were sustained at week 12 and year 1 
of the extension study. In the former placebo group (n=75), 
an increase in 6MWD of 51±64 m was observed at week 
12. In the overall population, 6MWD was 409±96 m at 1 
year (n=172), compared with 351±78 m at baseline (n=237). 
This represented an improvement of 51±62 m in the overall 
population (n=172). At 1 year in the overall population, NT-
proBNP changed by -416±1,321 pg/mL (n=149). At 1 year, 
WHO FC had improved/stabilized/worsened in 50%/45%/4% 
in the former riociguat group (n=117), 39%/59%/2% in 
the former placebo group (n=59), and 47%/50%/3% in the 
overall population (n=176), respectively. The proportion 
of patients in the overall population in WHO FC I/II/III/IV 
at 1 year was 14%/54%/31%/1% (n=177) compared with 
1%/31%/65%/3% (n=236) at baseline, respectively. Overall, 
16% of patients experienced clinical worsening during the 
study period. The estimated rate of clinical worsening-free 
survival at 1 year was 88% (95% CI: 83–92). The improve-
ment in Borg dyspnea score seen in the former riociguat 
group (n=154) was maintained at week 12 (n=145) and 
year 1 (n=113), while patients in the former placebo group 
showed improved scores after the switch to riociguat at 
week 12 (n=75) and year 1 (n=58). The authors concluded 
that long-term treatment with riociguat showed a favorable 
benefit–risk profile in the studied population.31
Pharmacoeconomics
The average wholesale price (AWP) of a 30-day supply 
(90 tablets) of riociguat, regardless of the strength, is 
US$9,270 (as of October 2014).32 The annual cost of the 
medication has been estimated to be US$90,000 (as of 
October 2013).33 A budgetary impact analysis of adding 
riociguat to a US health plan’s formulary for treatment of 
either PAH or CTEPH was conducted.34 A decision analytic 
tool was developed to estimate the impact of riociguat on 
per-member per-month (PMPM) and per-member per-year 
(PMPY) bases in health care plans. Drug costs were based 
on 2013 AWP. In a hypothetical plan population of one 
million members, the model estimated that seven patients 
with PAH and two with CTEPH would be suitable for phar-
macotherapy (based on published prevalence data). Overall, 
three patients were receiving riociguat in this model. The 
incremental cost increase to members of the health care 
plan to provide coverage for riociguat to three patients was 
US$0.27 per year and US$0.02 per month. A cost–utility 
analysis of bosentan and riociguat was conducted from 
a third-party payer perspective.35 Bosentan was selected 
because it is the only other medication studied in a random-
ized trial fashion in the CTEPH population.23 Data for this 
analysis were extrapolated from a Phase III clinical trial in 
the CTEPH population.11 The economic model demonstrated 
that riociguat is cost-effective at a threshold of US$100,000 
per quality-adjusted life-year gained after 1 year of treatment 
and was more cost-effective than bosentan after 2 years 
of therapy and beyond. While the latter two analyses are 
mathematical models, they both demonstrated that addition 
of riociguat to a health care plan had favorable financial 
outcomes. Both of these pharmacoeconomic analyses were 
conducted by personnel of the pharmaceutical company 
producing riociguat and the latter study was not extensively 
peer-reviewed.






Riociguat starting dose is 1 mg given by PO TID and is 
increased by 0.5 mg PO TID no more than once every 2 weeks 
to a maximum dose of 2.5 mg PO TID. Doses should be 
taken 6–8 hours apart. A lower starting dose of 0.5 mg PO 
TID is recommended for patients who may not tolerate the 
blood pressure-lowering effects of riociguat or who are taking 
strong cytochrome P450 (CYP) 3A4/P-glycoprotein (P-gp) 
inhibitors. Dose titrations may occur if SBP is .95 mmHg 
and there are no symptoms of hypotension. The dose of rio-
ciguat should be decreased by 0.5 mg PO TID for symptoms 
of hypotension.36
Riociguat does not cause rebound PH after sudden with-
drawal but should be retitrated for dose interruptions of 3 days 
or longer.36 Riociguat absorption does not exhibit significant 
food effects and can be administered without regard for 
meals.28,36 Riociguat undergoes rapid enteral absorption but 
is a low solubility compound with a pKa of 4.3. Therefore, 
gastric acid-reducing agents significantly affect riociguat’s 
bioavailability and should be administered at least 1 hour 
before or after riociguat.28,36 Riociguat metabolism and excre-
tion fractions demonstrate significant interpatient variability, 
and thus hepatic and renal impairment will have variable 
clinical effects between patients.28
Drug interactions, contraindications, and 
warnings
Riociguat is principally metabolized via the CYP1A1 and 
CYP3A4/5 isoenzymes and is a substrate of the P-gp/BCRP 
efflux enzymes. Potent inducers or inhibitors of these 
enzymes may pose clinically significant drug interactions. 
Strong CYP3A4/P-gp inhibitors may necessitate riociguat 
dose reductions. Combusted tobacco products may increase 
riociguat dose requirements via CYP1A1 induction.35 
Riociguat is contraindicated in patients receiving concomitant 
PDE5 inhibitors, nonspecific PDE inhibitors, or NO donors 
due to a risk of potentially fatal hypotensive complications.35 
The use of riociguat is not recommended in patients with a 
creatinine clearance ,15 mL/min, those receiving dialysis, 
or with Child-Pugh C liver disease.7 Riociguat should not 
be used in those with pulmonary veno-occlusive disease. In 
placebo-controlled trials, serious bleeding occurred more 
frequently in this population (2.4% vs 0%) and included one 
fatal case of hemoptysis.35
Riociguat is contraindicated in pregnancy (Category X).35 
Women of reproductive potential must enroll in a risk evalu-
ation and mitigation strategy (REMS) program to receive the 
medication. This program requires monthly pregnancy testing 
and using two acceptable methods of contraception until 
1 month after the therapy has been discontinued. Nursing 
mothers should not initiate or continue riociguat. Riociguat 
is only available through specialty pharmacies enrolled in 
the REMS program.
Role in therapy
Riociguat’s role in the management of CTEPH will continue 
to evolve as more clinical experience and post-marketing data 
are available. Currently, it is paramount that patients with 
CTEPH continue to be referred early to a center with exper-
tise in PEA for assessment of procedural candidacy.6,14,37–40 
A recent systematic review including 19 studies with 2,729 
patients described outcomes after PEA.41 Before PEA, 
60%–100% of patients were WHO FC III or IV. This percent-
age of patients with WHO FC III or IV symptoms decreased 
to 0%–21% after PEA. Residual PH symptoms were present 
in 11%–35% of the patients after PEA. Five-year survival 
was in the range of 74%–89%. The median 30-day mortal-
ity after PEA was 8%. The improvement in 6MWD 2 years 
after PEA was 96 m.42
Initiation of riociguat prior to surgical assessment at 
a center with expertise in PEA, while shown to improve 
symptomatic disease, is discouraged as it has the potential 
to delay an often curative procedure.14,40 One retrospective 
study indicated that there was no difference in outcomes 
with preoperative pharmacotherapy, but there was a delay in 
PEA in those treated with pharmacotherapy first.43 One small 
randomized, controlled trial demonstrated an improvement 
in 6MWD by a mean of 33 m at 16 weeks when compar-
ing preoperative pharmacotherapy with bosentan versus 
placebo. There is concern that this delay from diagnosis to 
PEA will delay the operation unnecessarily making removal 
of the organized thrombus more difficult.14 Preoperative 
riociguat for PEA-eligible patients not assessed for PEA at 
a center with expertise remains an area for future research. 
Currently, riociguat is a novel therapeutic option in both the 
inoperable population and those with symptomatic disease 
despite PEA.4,40
Conclusion
PEA remains the treatment of choice for management of 
CTEPH for operable candidates. Riociguat represents a novel 
option in inoperable CTEPH and those with symptomatic 
disease despite PEA. Riociguat is a first-in-class oral medi-
cation that is the sole agent approved for CTEPH and which 




Riociguat’s role in CTePH
appears to be effective at improving symptomatology and 
is well tolerated.
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